R-CHOP plus ibrutinib followed by ibrutinib maintenance induced an ORR of 90% after 4 cycles and 85% at the end of induction. Adding ibrutinib to standard-of-care (SOC) R-CHOP resulted in a 77.7% ...
Add Yahoo as a preferred source to see more of our stories on Google. Few agents define SoC for first-line DLBCL Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has ...
Non-Hodgkin lymphoma (NHL) is a group of hematologic malignancies that originate from lymphocytes known as B or T cells. This occurs in the lymphatic system and is commonly characterized by swollen ...
Spleen tissue from a mouse model: highlighted in dark brown are immune cells characteristic of DLBCL, shown here clustering spontaneously without external immune stimulation. A research team at the ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results